COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04150913
Recruitment Status : Not yet recruiting
First Posted : November 5, 2019
Last Update Posted : July 9, 2020
Kite, A Gilead Company
Information provided by (Responsible Party):
Marcela V. Maus, M.D.,Ph.D., Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2024